Clinical trials: Relapsed/ Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
The purpose of this study is to determine the side effects of treatment with the monoclonal antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the dose that should be recommended for use in…
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia
- Trial name
- NCT01452334
- Testing
- BMS-936559 (Anti PD-L1)
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06160609
- Testing
- Belantamab Mafodotin, GSK3174998
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07667868
- Testing
- BP2202
- Volunteers
- 18 people
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
Multiple Myeloma
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
The purpose of this study is to compare bortezomib, dexamethasone and cyclophosphamide to bortezomib and dexamethasone alone for primary refractory or relapsed multiple myeloma.
- Trial name
- NCT00813150
- Testing
- Dexamethasone, Bortezomib, Cyclophosphamide
- Where
- 40 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM.
- Trial name
- DREAMM-3 (NCT04162210)
- Testing
- Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)
- Where
- 136 sites in United States, Australia and 17 more
- Volunteers
- 325 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have…
- Trial name
- NCT05027594
- Testing
- NMS-03597812, NMS-03597812 + dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nerviano Medical Sciences
Relapsed or Refractory Multiple Myeloma
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization.
- Trial name
- NCT05463939
- Testing
- Teclistamab
- Sponsor
- Janssen Research & Development, LLC
Hematological Malignancies
A Study of TQB3820 in Patients With Hematological Malignancies
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the…
- Trial name
- NCT05020639
- Testing
- TQB3820 tablets
- Where
- 2 sites in China
- Volunteers
- 116 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Multiple Myeloma
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
The purpose of this study is to assess the safety and tolerability of Elotuzumab when given in combination with Lenalidomide and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (MM) in Japan.
- Trial name
- NCT01241292
- Testing
- BMS-901608 (Elotuzumab) 10 mg, BMS-901608 (Elotuzumab) 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Refractory or Relapsed Multiple Myeloma
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple…
- Trial name
- NCT06952478
- Testing
- CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)
- Where
- Taiwan
- Volunteers
- 473 people
- Sponsor
- Celltrion
Multiple Myeloma
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM).
- Trial name
- NCT06504524
- Testing
- Elranatamab, Standard of Care
- Where
- 2 sites in United States, Germany
- Volunteers
- 633 people
- Sponsor
- Pfizer
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00017069
- Testing
- arsenic trioxide, dexamethasone
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell
- Trial name
- NCT04272151
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma.
- Trial name
- NCT01023880
- Testing
- CEP-18770
- Where
- 13 sites in United States
- Volunteers
- 62 people
- Sponsor
- Cephalon
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed and/or Relapsed-refractory Multiple Myeloma
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen.
- Trial name
- NCT01897714
- Testing
- Melflufen, Dexamethasone
- Where
- 7 sites in United States, Denmark and 3 more
- Volunteers
- 75 people
- Sponsor
- Oncopeptides AB
Relapsed/Refractory Multiple Myeloma
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
- Trial name
- NCT03169361
- Testing
- Ixazomib
- Where
- Japan
- Volunteers
- 774 people
- Sponsor
- Takeda
Multiple Myeloma
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
It is a dose expansion, open-label, phase Ib study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of CT103A in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT05698303
- Testing
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.